Futura Medical (FUM)

 

FUM Share PerformanceMore

52 week high75.50 19/09/16
52 week low28.00 19/09/17
52 week change -44.50 (-61.38%)
4 week volume7,482,070 24/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Directors' / PDMR Dealing and Grant of Options

RNS Number: 5653Q Futura Medical PLC 13 September 2017 13 September 2017 Futura Medical plc ("Futura" or "the Company") Directors' / PDMR Dealing and Grant of Options Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that on 12 September 2017 it granted options over a total of 1,4...

Futura net losses narrow

Futura Medical's first half net losses narrowed to 1.60m - down from 1.89m a year ago. It said this reflected the planned red...

Interim Results

RNS Number: 4354Q Futura Medical PLC 12 September 2017 For immediate release 12 September 2017 Futura Medical plc ("Futura" or "the Company") Interim Results for the six months 30 June 2017 Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce its interim results for the six...

Notification of Major Interest in Shares

RNS Number: 6081P Futura Medical PLC 01 September 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Futura Medical PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the no...

CSD500: Termination of Licensing Agreement

RNS Number: 7773O Futura Medical PLC 23 August 2017 For immediate release 23 August 2017 Futura Medical plc CSD500: Notice of Termination of Licensing Agreement Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that Church & Dwight Co Inc, with which the Company signed a li...

Notification of Half Year Results

RNS Number: 7008O Futura Medical PLC 22 August 2017 For immediate release 22 August 2017 Futura Medical plc ("Futura" or "the Company") Notification of Half Year Results Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will announce its interim results for the six months ended 30 June 2017...

Investor Presentation on MED2002

RNS Number: 9991J Futura Medical PLC 04 July 2017 For immediate release 4 July 2017 Futura Medical plc ("Futura" or the "Company") Investor Presentation on MED2002 Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that the Company is today presenting to institutional in...

Result of AGM

RNS Number: 1158I Futura Medical PLC 14 June 2017 For immediate release 14 June 2017 Futura Medical plc ("Futura" or "the Company") Result of AGM Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, confirms that all resolutions were duly passed at its Annual General Meeting held today. For any...

Fundamental DataMore

EPS-3.65
Dividend yield0 %

Equity Research (FUM)

hardman & co
Futura Medical plc
25/11/2015
FUM has advanced transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. 2015 was expected to be a busy year for...
hardman & co
Futura Medical plc
09/09/2015
Futura Medical has advanced transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. 2015 was expected to be a busy...
hardman & co
Futura Medical plc
14/07/2015
Futura Medical has proprietary transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. Headline results from a...

Latest discussion posts More

  • Why was only one dose used?

    Some information for you on why only one concentration of med2002 was selected for phase 2. 1. In early Phase 1 work at higher doses, a high side effect profile was ...
    19-Sep-2017
    Aberdeen_investor
  • Re: What about the other half for crying...

    Absolutely oil. The ED treatment will be prescribed for the man, however if the female has some sort of say in the matter, the couple could prefer to get med2002 as opposed to ...
    15-Sep-2017
    Aberdeen_investor
  • Re: What about the other half for crying...

    The Webcast (time 24:10) covered the research into 'medicalising' the 'spontaneity & intimacy' benefits of MED2002 (presumably for women) with results in 6 weeks. It will be ...
    15-Sep-2017
    oilovlam

Users' HoldingsMore

Users who hold Futura Medical also hold..
LLOYDS GRP.22%
SIRIUS MINERALS18%
TESCO12%
BARCLAYS12%
BP12%

Codes & Symbols

ISINGB0033278473
SymbolsFUM, LSE:FUM, FUM.L, FUM:LN, LON:FUM, XLON:FUM